Gisbert Schneider
Gisbert Schneider
Verified email at - Homepage
Cited by
Cited by
Designing antimicrobial peptides: form follows function
CD Fjell, JA Hiss, REW Hancock, G Schneider
Nature reviews Drug discovery 11 (1), 37-51, 2012
Computer-based de novo design of drug-like molecules
G Schneider, U Fechner
Nature Reviews Drug Discovery 4 (8), 649-663, 2005
Counting on natural products for drug design
T Rodrigues, D Reker, P Schneider, G Schneider
Nature chemistry 8 (6), 531-541, 2016
“Scaffold‐hopping” by topological pharmacophore search: a contribution to virtual screening
G Schneider, W Neidhart, T Giller, G Schmid
Angewandte Chemie International Edition 38 (19), 2894-2896, 1999
Comparison of support vector machine and artificial neural network systems for drug/nondrug classification
E Byvatov, U Fechner, J Sadowski, G Schneider
Journal of chemical information and computer sciences 43 (6), 1882-1889, 2003
Virtual screening: an endless staircase?
G Schneider
Nature Reviews Drug Discovery 9 (4), 273-276, 2010
Deep learning in drug discovery
E Gawehn, JA Hiss, G Schneider
Molecular informatics 35 (1), 3-14, 2016
Virtual screening and fast automated docking methods
G Schneider, HJ Böhm
Drug discovery today 7, 64-70, 2002
Automating drug discovery
G Schneider
Nature reviews drug discovery 17 (2), 97-113, 2018
PocketPicker: analysis of ligand binding-sites with shape descriptors
M Weisel, E Proschak, G Schneider
Chemistry Central Journal 1 (1), 1-17, 2007
Support vector machine applications in bioinformatics.
E Byvatov, G Schneider
Applied bioinformatics 2 (2), 67-77, 2003
Scaffold architecture and pharmacophoric properties of natural products and trade drugs: application in the design of natural product-based combinatorial libraries
ML Lee, G Schneider
Journal of combinatorial chemistry 3 (3), 284-289, 2001
Predicting drug metabolism: experiment and/or computation?
J Kirchmair, AH Göller, D Lang, J Kunze, B Testa, ID Wilson, RC Glen, ...
Nature reviews Drug discovery 14 (6), 387-404, 2015
Optimized Particle Swarm Optimization (OPSO) and its application to artificial neural network training
M Meissner, M Schmuker, G Schneider
BMC bioinformatics 7 (1), 1-11, 2006
Concepts of artificial intelligence for computer-assisted drug discovery
X Yang, Y Wang, R Byrne, G Schneider, S Yang
Chemical reviews 119 (18), 10520-10594, 2019
Development of a virtual screening method for identification of “frequent hitters” in compound libraries
O Roche, P Schneider, J Zuegge, W Guba, M Kansy, A Alanine, ...
Journal of medicinal chemistry 45 (1), 137-142, 2002
Generative Recurrent Networks for De Novo Drug Design
A Gupta, AT Müller, BJH Huisman, JA Fuchs, P Schneider, G Schneider
Molecular informatics 37 (1-2), 1700111, 2018
De novo design of molecular architectures by evolutionary assembly of drug-derived building blocks
G Schneider, ML Lee, M Stahl, P Schneider
Journal of computer-aided molecular design 14 (5), 487-494, 2000
Artificial neural networks for computer-based molecular design
G Schneider, P Wrede
Progress in biophysics and molecular biology 70 (3), 175-222, 1998
Helicobacter pylori HtrA is a new secreted virulence factor that cleaves E‐cadherin to disrupt intercellular adhesion
B Hoy, M Löwer, C Weydig, G Carra, N Tegtmeyer, T Geppert, P Schröder, ...
EMBO reports 11 (10), 798-804, 2010
The system can't perform the operation now. Try again later.
Articles 1–20